NCT06992336
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 2 words
- Interventions modified
- Enrollment target: 411 to 430
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
iDFS
Timeframe: from randomization to any of the following events: local or distant relapse; contralateral breast caner, death of any cause,assessed up to 36 months.
Secondary (3)
dDFS
OS
ctDNA clearance
Arms and interventions
AExperimental
Apatinib 8mg qd PO,357days Camrelizumab 200mg i.v. Q3W or immunotherapy continued as in the NAC(17cycles in total). Capecitabine 1000 or 1250 mg/m2 BID day1-14
BActive comparator
Investigator's choice. If immunotherapy was used in the NAC setting, it was required to be used after NAC for up to 1 years.
Drugs: Apatinib, Camrelizumab, Capecitabine
Sites
1 site in 1 country
- Sun Yat-sen Memorial HospitalGuangzhou, Guangodng, China